Holen Sie sich die Stockscreener-App
14.29
2.95%
0.41
Vorhandelsmarkt:
14.59
0.30
+2.10%
Schlusskurs vom Vortag:
$13.88
Offen:
$14.09
24-Stunden-Volumen:
274.61K
Relative Volume:
0.56
Marktkapitalisierung:
$984.26M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-9.4636
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+4.92%
1M Leistung:
+1.06%
6M Leistung:
+46.11%
1J Leistung:
+44.64%
1-Tages-Spanne:
$13.88
$14.38
1-Wochen-Bereich:
$13.58
$14.63
52-Wochen-Spanne:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.29 | 984.26M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase - Investing.com
Zymeworks in Focus for Insider Activity: Catalysts Ahead - Benzinga
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - The Korea Bizwire
Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics - TipRanks
Zymeworks says it has enough cash to operate through H2 2027 - Seeking Alpha
Zymeworks Unveils 2025 Pipeline Strategy: Multiple INDs Planned, $324M Cash Position Supports Growth - StockTitan
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade - Yahoo Finance
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock By Investing.com - Investing.com Australia
Zymeworks chief scientific officer sells shares worth $316,390 By Investing.com - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) CEO Sells $854,781.72 in Stock - MarketBeat
Insider Selling: Zymeworks Inc. (NYSE:ZYME) EVP Sells 11,110 Shares of Stock - MarketBeat
Paul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks chief scientific officer sells shares worth $316,390 - Investing.com
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap Up After Insider Buying Activity - Defense World
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - MarketBeat
Ecor1 Capital, Llc Buys 157,880 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 58,988 Shares - MarketBeat
Geode Capital Management LLC Grows Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 11,958 Shares of Stock - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Purchases 16,692 Shares - MarketBeat
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase By Investing.com - Investing.com Canada
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase - Investing.com India
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Barclays PLC - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Shares Bought by State Street Corp - MarketBeat
Zymeworks (NYSE:ZYME) Shares Down 2.4%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):